CA3242602A1 - Sel de benzoate de 5-methoxy-n,n-dimethyltryptamine - Google Patents

Sel de benzoate de 5-methoxy-n,n-dimethyltryptamine

Info

Publication number
CA3242602A1
CA3242602A1 CA3242602A CA3242602A CA3242602A1 CA 3242602 A1 CA3242602 A1 CA 3242602A1 CA 3242602 A CA3242602 A CA 3242602A CA 3242602 A CA3242602 A CA 3242602A CA 3242602 A1 CA3242602 A1 CA 3242602A1
Authority
CA
Canada
Prior art keywords
dimethyltryptamine
methoxy
benzoate salt
salt
dmt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3242602A
Other languages
English (en)
Inventor
Cosmo FEILDING-MELLEN
Jason Gray
Timothy Mason
Cosima Agnes RUDD GRETTON
Frank Wiegand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beckley Psytech Ltd
Original Assignee
Beckley Psytech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2118007.0A external-priority patent/GB202118007D0/en
Priority claimed from GBGB2118008.8A external-priority patent/GB202118008D0/en
Priority claimed from GBGB2118005.4A external-priority patent/GB202118005D0/en
Priority claimed from GBGB2118011.2A external-priority patent/GB202118011D0/en
Priority claimed from GBGB2118006.2A external-priority patent/GB202118006D0/en
Priority claimed from GBGB2118095.5A external-priority patent/GB202118095D0/en
Priority claimed from GBGB2118099.7A external-priority patent/GB202118099D0/en
Priority claimed from GBGB2118156.5A external-priority patent/GB202118156D0/en
Priority claimed from GBGB2212113.1A external-priority patent/GB202212113D0/en
Priority claimed from GBGB2212117.2A external-priority patent/GB202212117D0/en
Application filed by Beckley Psytech Ltd filed Critical Beckley Psytech Ltd
Publication of CA3242602A1 publication Critical patent/CA3242602A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Un procédé de synthèse du sel de benzoate de 5-MeO-DMT comprend l'étape de traitement du sel de chlorhydrate de 5-MeO-DMT avec une base, avant l'ajout d'acide benzoïque.
CA3242602A 2021-12-13 2022-12-13 Sel de benzoate de 5-methoxy-n,n-dimethyltryptamine Pending CA3242602A1 (fr)

Applications Claiming Priority (29)

Application Number Priority Date Filing Date Title
GBGB2118008.8A GB202118008D0 (en) 2021-12-13 2021-12-13 Combination Pharmaceutical composition
GB2118006.2 2021-12-13
GB2118008.8 2021-12-13
GB2118011.2 2021-12-13
GBGB2118005.4A GB202118005D0 (en) 2021-12-13 2021-12-13 Methods of synthesis
GB2118007.0 2021-12-13
GB2118005.4 2021-12-13
GBGB2118011.2A GB202118011D0 (en) 2021-12-13 2021-12-13 Methods of treatment
GBGB2118006.2A GB202118006D0 (en) 2021-12-13 2021-12-13 Methods of treatment
GBGB2118007.0A GB202118007D0 (en) 2021-12-13 2021-12-13 Methods of treatment
GB2118095.5 2021-12-14
GBGB2118095.5A GB202118095D0 (en) 2021-12-14 2021-12-14 Combination pharmaceutical composition
GB2118099.7 2021-12-14
GBGB2118099.7A GB202118099D0 (en) 2021-12-14 2021-12-14 Methods of synthesis
GBGB2118156.5A GB202118156D0 (en) 2021-12-15 2021-12-15 Methods of synthesis
GB2118156.5 2021-12-15
GB2118293.6 2021-12-16
GB202118295 2021-12-16
GB2118305.8 2021-12-16
GB202118293 2021-12-16
GB202118305 2021-12-16
GB2118295.1 2021-12-16
GB202118309 2021-12-16
GB2118309.0 2021-12-16
GB2212113.1 2022-08-19
GBGB2212113.1A GB202212113D0 (en) 2022-08-19 2022-08-19 Method of synthesis
GBGB2212117.2A GB202212117D0 (en) 2022-08-19 2022-08-19 Method of synthesis
GB2212117.2 2022-08-19
PCT/GB2022/053208 WO2023111544A2 (fr) 2021-12-13 2022-12-13 Sel de benzoate de 5-méthoxy-n,n-diméthyltryptamine

Publications (1)

Publication Number Publication Date
CA3242602A1 true CA3242602A1 (fr) 2023-06-22

Family

ID=84627509

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3242602A Pending CA3242602A1 (fr) 2021-12-13 2022-12-13 Sel de benzoate de 5-methoxy-n,n-dimethyltryptamine

Country Status (4)

Country Link
EP (1) EP4448488A2 (fr)
AU (1) AU2022413759A1 (fr)
CA (1) CA3242602A1 (fr)
WO (1) WO2023111544A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11759452B2 (en) 2020-05-08 2023-09-19 Psilera Inc. Compositions of matter and pharmaceutical compositions
JP2024521747A (ja) 2021-05-25 2024-06-04 アタイ セラピューティクス， インコーポレイテッド 新しいｎ，ｎ－ジメチルトリプタミン塩および結晶塩形態
AU2023246548A1 (en) * 2022-03-27 2024-11-07 GH Research Ireland Limited 5-methoxy-n.n-dimethyltryptamine for the treatment of psychomotor retardation
US12264131B2 (en) 2022-08-19 2025-04-01 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
EP4618946A1 (fr) * 2022-11-14 2025-09-24 Beckley Psytech Limited Formulations de 5-meo-dmt
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
WO2025054397A1 (fr) * 2023-09-08 2025-03-13 Atai Therapeutics, Inc. Formulations parentérales pour n, n-diméthyltryptamine (dmt) et analogues de dmt, leurs méthodes de fabrication et leurs méthodes d'utilisation
WO2025076151A1 (fr) * 2023-10-02 2025-04-10 Atai Therapeutics, Inc. N-n-diméthyltryptamine (dmt) et compositions de film transmucosal oral analogique à base de dmt, leurs procédés de production et leurs méthodes d'utilisation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11723894B2 (en) * 2017-10-26 2023-08-15 Terran Biosciences, Inc. Combination product for the treatment of neurological and/or psychiatric disorders
KR20210154967A (ko) * 2019-02-22 2021-12-21 지에이치 리서치 아일랜드 리미티드 정신 장애를 치료하는데 사용하기 위한 5-메톡시-n,n-디메틸트립타민 (5-meo-dmt)을 포함하는 조성물
BR112022021831A2 (pt) * 2020-05-01 2022-12-13 Emergex Usa Corp Dispositivos de liberação transdérmica de fármacos tendo micro projeções revestidas com psilocibina, dietilamida do ácido lisérgico ou 3,4-metilenodioximetanfetamina
KR20230024378A (ko) * 2020-06-12 2023-02-20 벡클리 싸이테크 리미티드 5-메톡시-n, n-디메틸트립타민의 벤조에이트 염을 포함하는 조성물

Also Published As

Publication number Publication date
AU2022413759A1 (en) 2024-06-27
EP4448488A2 (fr) 2024-10-23
WO2023111544A2 (fr) 2023-06-22
WO2023111544A3 (fr) 2023-07-20

Similar Documents

Publication Publication Date Title
CA3242602A1 (fr) Sel de benzoate de 5-methoxy-n,n-dimethyltryptamine
EP4279070A3 (fr) Composition comprenant un sel de benzoate de 5-méthoxy-n,n-diméthyltryptamine
NZ766978A (en) Atr inhibitor and application thereof
EP4249054A3 (fr) Fluorophényle bêta-hydroxyéthylamines et leur utilisation dans le traitement de l'hyperglycémie
WO2024083255A8 (fr) Dérivé d'aminoquinazoline substitué par benzyle ou thiénylméthylène et son utilisation en tant qu'agent de dégradation de sos1
WO2016175555A3 (fr) Nouveaux dérivés de 4-méthoxy pyrrole ou leurs sels, et composition pharmaceutique les comprenant
WO2018232005A3 (fr) Composés et nanostructures antimicrobiens
PH12022550531A1 (en) Irak inhibitor and preparation method therefor and use thereof
WO2017164576A8 (fr) Nouvelle forme cristalline de sel de 1-(5-(2,4-difluorophényl)-1-((3-fluorophényl)sulfonyl)-4-méthoxy-1h-pyrrol-3-yl)-n-méthylméthanamine
WO2008045673A3 (fr) Acides carboxyliques de quinolone, dérivés de ceux-ci et leurs procédés de préparation et d'utilisation
WO2023141432A3 (fr) Inhibiteurs d'apol1 et méthodes d'utilisation
RU2003137600A (ru) Крем для лечения солнечных ожогов
EP4477222A3 (fr) Formes cristallines de c21h22ci2n4o2
MX2024010828A (es) Procedimiento para preparar 4-metil-2-propan-2-il-piridin-3-carbon itrilo.
WO2017039112A3 (fr) Procédé de production de membrane de traitement d'eau, membrane de traitement d'eau produite à l'aide de celui-ci, et module de traitement d'eau comprenant la membrane de traitement d'eau
AR052301A1 (es) Procedimiento de preparacion de un monoclorhidrato. formas cristalinas y composiciones farmaceuticas
HK1212154A1 (en) Compositions and methods for improving the compatibility of water soluble herbicide salts
WO2011092720A3 (fr) Composition pharmaceutique de prasugrel et ses sels pharmaceutiquement acceptables
WO2024086246A3 (fr) 3,4 a, 5, 7, 8, 8 a-hexahydro-4h-thiop yrano [4,3-djpyrimidin-4-ones substituées en position 2 pour le traitement des plaies
WO2013062332A3 (fr) Composition anti-vieillissement vasculaire comprenant du syringarésinol
RU2014132856A (ru) Способ удаления серы из волокна с применением водного раствора кислоты
RU2021125289A (ru) Способ снижения адреналина и норадреналина миокарда
WO2020116589A9 (fr) Procédé de production d'un composé amide fluorovinylique
PL3988524T3 (pl) Sposób wytwarzania propano-1,2-diolu
MX2022005260A (es) Sal de adicion acida de regulador rorgamma.

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241204

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241204

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241204

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251201

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251201